Anti-TIGIT Plus Immunotherapy 'Promising' in NSCLC, Esophageal Cancer
(MedPage Today) -- Combination treatment with an investigational anti-TIGIT drug plus a PD-L1 inhibitor was well tolerated and demonstrated promising activity in patients with metastatic non-small cell lung cancer (NSCLC) and esophageal cancer...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Esophagus Cancer | Hematology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer